Uveal melanoma research

Patient care and uveal melanoma research are closely linked. It is necessary to work together on: 

• the genetic causes of the disease, in particular predisposition genes 
• the fight against metastatic relapse, one of the main risks of the disease 
• developing biomarkers to assess the efficacy of immunotherapies such as tebentafusp or anti-PD1 
• the design of new immunotherapy strategies for patients insensitive to tebentafusp 
• participation in major international clinical trials 
• development of new radiological criteria for treatment efficacy 
• or the development of therapeutic vaccines, notably on the trail of a mutation likely to make melanomas more visible to the immune system.